Verano Holdings (VRNO) Receivables (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Receivables of $32.1 million for Q1 2026, down 19.68% year-over-year from $40.0 million in Q1 2025, and up 3.91% quarter-over-quarter from $30.9 million in Q4 2025.
Verano Holdings (VRNO) Receivables (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Receivables for 6 consecutive years, with $32.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables fell 19.68% year-over-year to $32.1 million; the TTM figure through Mar 2026 stood at $32.1 million (down 19.68% YoY), while the FY2025 annual figure was $30.9 million, down 23.18% from the prior year.
- Receivables rose to $32.1 million in Q1 2026 per VRNO's latest filing, from $30.9 million in the prior quarter.
- Across five years, Receivables topped out at $46.9 million in Q3 2024 and bottomed at $13.3 million in Q2 2022.
- Historically, Receivables has averaged $31.5 million across 5 years, with a median of $32.3 million in 2025.
- Annual changes were most pronounced in 2023 — Receivables soared 135.11% — and 2025, when it slumped 30.85%.
- Verano Holdings' Receivables stood at $16.6 million in 2022, then jumped by 135.11% to $39.0 million in 2023, then rose by 3.29% to $40.3 million in 2024, then dropped by 23.18% to $30.9 million in 2025, then advanced by 3.91% to $32.1 million in 2026.
- Business Quant data shows VRNO's Receivables at $32.1 million in Q1 2026, $30.9 million in Q4 2025, and $32.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 3.07 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 3.49 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 1.57 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 5.84 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 310.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 3.67 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 887.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.15 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 1.08 Bn |
| 10 | Verano Holdings | 438.82 Mn | 353.62 Mn | 99.70 Mn | 28.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.79 Mn |
| Mar 31, 2026 | 32.14 Mn |
| Dec 31, 2025 | 30.93 Mn |
| Sep 30, 2025 | 32.46 Mn |
| Jun 30, 2025 | 30.76 Mn |
| Mar 31, 2025 | 40.02 Mn |
| Dec 31, 2024 | 40.26 Mn |
| Sep 30, 2024 | 46.94 Mn |
| Jun 30, 2024 | 43.21 Mn |
| Mar 31, 2024 | 41.93 Mn |
| Dec 31, 2023 | 38.98 Mn |
| Sep 30, 2023 | 34.32 Mn |
| Jun 30, 2023 | 28.66 Mn |
| Mar 31, 2023 | 18.25 Mn |
| Dec 31, 2022 | 16.58 Mn |
| Sep 30, 2022 | 15.20 Mn |
| Jun 30, 2022 | 13.25 Mn |
| Dec 31, 2021 | 17.41 Mn |